Lysergic acid 2,4-dimethylazetidide
Chemical compound / From Wikipedia, the free encyclopedia
Lysergic acid 2,4-dimethylazetidide (LA-SS-Az, LSZ) is an analog of LSD developed by the team led by David E. Nichols at Purdue University.[2][3] It was developed as a rigid analog of LSD with the diethylamide group constrained into an azetidine ring in order to map the binding site at the 5-HT2A receptor. There are three possible stereoisomers around the azetidine ring, with the (S,S)-(+) isomer being the most active, slightly more potent than LSD itself in drug discrimination tests using trained rats.[4]
Clinical data | |
---|---|
Other names | Lysergic acid 2,4-dimethylazetidine, Diazedine, Lambda, LSZ |
Routes of administration | Oral |
Legal status | |
Legal status | |
Identifiers | |
| |
|
|
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
Chemical and physical data | |
Formula | C21H25N3O |
Molar mass | 335.451 g·mol−1 |
3D model (JSmol) |
|
| |
| |
NY (what is this?) (verify) |
There have been several unconfirmed reports of lysergic acid 2,4-dimethylazetidide being synthesized in illicit laboratories and distributed on blotter paper or in liquid solution under names such as "diazedine" and "λ".[5][6]
In 2013 LSZ also appeared on some designer drug and research chemical markets in the UK.[7] LSZ later gained international popularity through a small cluster of mail-order novel psychedelic shops that appeared in 2012.[8]